Abstract: SA-PO0800
Patient Profiles, Treatment Patterns, and Economic Burden Among Users of Avacopan in the United States
Session Information
- Glomerular Research: Design, Registries, Surveys, and Epidemiology
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Geetha, Duvuru, Johns Hopkins University, Baltimore, Maryland, United States
- Ibiloye, Elizabeth A., Amgen Inc, Thousand Oaks, California, United States
- Kathe, Niranjan, Amgen Inc, Thousand Oaks, California, United States
- Bozeman, Alana, Amgen Inc, Thousand Oaks, California, United States
- Oh, Sam S., Amgen Inc, Thousand Oaks, California, United States
- Multani, Jasjit, IQVIA Inc, Wayne, Pennsylvania, United States
- Chang, Hsiu-Ching, IQVIA Inc, Wayne, Pennsylvania, United States
- Yasuda, Marie, IQVIA Inc, Wayne, Pennsylvania, United States
- Chen, Chi-Chang, IQVIA Inc, Wayne, Pennsylvania, United States
- Merkel, Peter A., University of Pennsylvania, Philadelphia, Pennsylvania, United States
Background
Avacopan is an adjunctive treatment for adults with severe active granulomatosis with polyangiitis or microscopic polyangiitis (GPA/MPA). This study aimed to describe patient characteristics, treatment patterns, and economic burden among users of avacopan.
Methods
This retrospective cohort study examined US-based IQVIA PharMetrics® Plus claims data from Oct 2021 to Mar 2024. Patients age ≥18 years with ≥1 avacopan claim (index date: first avacopan claim date) and ≥12 months pre-index continuous data were included. Patient characteristics, economic burden, and GPA/MPA medication use were described in both the baseline and follow-up periods; avacopan treatment patterns were described in the follow-up period.
Results
Of 183 patients prescribed avacopan, rheumatologists (62.8%) were the most common prescribers; 98.9% received systemic glucocorticoids (GC) and/or other immunosuppressive therapy prior to initiating avacopan (Table 1); 59.6% had kidney involvement (8.2% on dialysis). The proportion of patients with ≥1 hospitalization and ≥1 emergency department visit was 49.7% and 50.8%, respectively, pre-avacopan (n=183), and 28.3% and 30.4% post-avacopan initiation (n=42). In 121 patients with a ≥90-day supply or ≥3 avacopan claims in the variable follow-up, 4.1% had a dialysis claim and 17.4% had evidence for relapse. Among those with 12-month follow-up (n=42), mean total oral prednisone-equivalent daily dose decreased from 19.8 mg to 10.6 mg between 90 days pre- and post-avacopan initiation.
Conclusion
A majority of users of avacopan with background immunosuppressive therapy had kidney involvement at baseline. Most patients have decreased GC exposure post-avacopan initiation.
Funding
- Commercial Support – Amgen Inc